The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments
Nathalia González-Jaramillo, Nicola Low, Oscar H. Franco
Abstract
Coronavirus disease 2019 (COVID-19) pandemic imposes a double burden on people with cardiovascular disease (CVD). About 40% of hospitalized COVID-19 patients have CVD COVID-19 mortality increases with comorbidities and age Correct evaluation of this double burden is challenged by three gaps in our knowledge: (1) the unknown confounding effect of age on mortality of CVD/COVID-19 patients, (2) the not fully understood effects of COVID-19 on the cardiovascular system, and (3) how antihypertensive medications targeting the renin-angiotensin system (RAS) might be associated with the severity of and survival to COVID-19 in CVD patients.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Epidemiology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseasePublic healthLead (geology)Coronavirus InfectionsIntensive care medicineInternal medicineVirologyPathologyInfectious disease (medical specialty)OutbreakGeologyGeomorphologyCOVID-19 Clinical Research StudiesCardiac Health and Mental HealthBlood Pressure and Hypertension Studies